STOCK TITAN

Niki BioSolutions (APM) regains Nasdaq $1 bid price compliance

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Niki BioSolutions, Inc., formerly known as Aptorum Group Limited, had previously been notified that its common stock traded below the $1.00 per share minimum bid price for 30 consecutive business days, triggering a deficiency under Nasdaq Listing Rule 5550(a)(2). The company was granted a 180‑day compliance period ending on September 1, 2026, during which it could regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days.

Nasdaq subsequently informed the company on August 4, 2026 that, from July 21, 2026 to August 3, 2026, the closing bid price of its common stock was at or above $1.00 per share for ten consecutive business days. As a result, Niki BioSolutions has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq has indicated that this matter is now closed.

Positive

  • Niki BioSolutions has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its stock maintained a closing bid of at least $1.00 per share for 10 consecutive business days, and Nasdaq has confirmed the matter is closed.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Minimum bid price requirement $1.00 per share Required minimum bid under Nasdaq Listing Rule 5550(a)(2) for continued listing
Noncompliance trigger period 30 consecutive business days Period during which the stock closed below $1.00 per share before deficiency notice
Compliance period length 180 calendar days Time allowed to regain compliance, ending September 1, 2026
Regaining compliance condition 10 consecutive business days Required span with closing price at or above $1.00 per share to regain compliance
Compliance achievement window July 21, 2026 to August 3, 2026 Dates when closing bid price was at or above $1.00 per share
Nasdaq Listing Rule 5550(a)(2) regulatory
"the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2)"
minimum bid price requirement market
"below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Capital Market market
"continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Listing Qualifications Department regulatory
"received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC"
A listing qualifications department is the part of a stock exchange that checks whether a company meets the exchange’s rules for being listed and staying listed. Think of it as a gatekeeper or building inspector: it reviews financial statements, disclosure practices and corporate governance, flags problems and can require fixes or remove a company’s shares. Investors care because its decisions affect whether a stock remains tradable and how much trust to place in a company’s reporting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Niki BioSolutions disclose that affects APM investors?

Niki BioSolutions disclosed that it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement after meeting the 10 consecutive business day closing bid condition, and Nasdaq has confirmed the compliance issue is closed.

Why was Niki BioSolutions (APM) previously out of compliance with Nasdaq rules?

The company was previously out of compliance because its common stock closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price for continued listing.

What was the compliance period Nasdaq gave Niki BioSolutions (APM)?

Nasdaq granted a 180‑calendar‑day compliance period, running until September 1, 2026, during which Niki BioSolutions could regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days.

How did Niki BioSolutions (APM) regain compliance with the Nasdaq bid rule?

The company regained compliance after its common stock’s closing bid price was at or above $1.00 per share for 10 consecutive business days, from July 21, 2026 through August 3, 2026, meeting Nasdaq’s specified condition.

What Nasdaq rule is relevant to Niki BioSolutions’ (APM) listing status?

The relevant rule is Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market; the company has now regained compliance with this rule.
false 0001734005 0001734005 2026-08-07 2026-08-07 0001734005 dei:FormerAddressMember 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 7, 2026

 

Niki BioSolutions, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware   001-38764    42-3265309
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

116 Village Boulevard, Suite 200, Princeton, NJ 08540
(Address of Principal Executive Offices, including zip code)

 

Registrant’s Telephone Number, Including Area Code: 609-951-2222

 

Aptorum Group Limited

17 Hanover Square

London W1S 1BN, United Kingdom

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.0001 per share   NIKI   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 8.01 Other Events.

 

As previously reported, on March 5, 2026, Niki BioSolutions, Inc. (formerly known as Aptorum Group Limited) (the “Company”) received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing price for the Company’s common stock had been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2).

 

The letter also indicated that the Company had a compliance period of 180 calendar days, or until September 1, 2026 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The letter further provided that if, at anytime during the Compliance Period, the Company’s common stock closed at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq would provide the Company with written confirmation that it had achieved compliance with the minimum bid price requirement.

 

On August 4, 2026, the Company received a letter from Nasdaq notifying the Company that for the last 10 consecutive business days, from July 21, 2026, to August 3, 2026, the closing bid price of the Company’s common stock had been at $1.00 per share or greater and, therefore, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this matter is now closed.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 7, 2026

 

  NIKI BIOSOLUTIONS, INC.
     
  By: /s/ Ian Huen
    Ian Huen
    Chief Executive Officer

 

 

2

 

Filing Exhibits & Attachments

4 documents